亚洲综合视频在线,国产中文成人精品久久久 ,国产视频福利

Global Biopharma Layoffs April 2026 Layoffs Global Biopharma companies including Novo Nordisk, IO Biotech, and BioNTech announce workforce reductions in April 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Novo Nordisk Full Year 2025 Financial Report Novo Nordisk Novo Nordisk's 2025 report highlights strong revenue growth driven by Wegovy? and Ozempic?, despite challenges in profit margins and rising costs. The company focuses on R&D, sustainability, and managing risks like competition and regulatory pressures.
Global Biopharma Layoffs October 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs September 2025 Layoffs The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
2025 H1 Global Pharma Earnings Panorama Financial statements A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.
Novo Nordisk H1 2025 Financial Reports Financial statements Novo Nordisk's Semaglutide generated $16.7B in H1 2025, surpassing Keytruda as the world's top-selling drug. Strong global and China sales drive growth despite competitive challenges.
Novo Nordisk Targets Wegovy Growth with New Strategy Novo Nordisk Novo Nordisk offers a discounted Wegovy price for new patients and launches the “Choose the Real Thing” campaign as the FDA ends compounded semaglutide sales. The company also intensifies legal action against compounders amid rising competition.
Top 10 Best-Selling Drugs in Q1 2025 Market Trend Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
Novo Nordisk CEO Lars Fruergaard J?rgensen Resigns Novo Nordisk Novo Nordisk announces CEO Lars Fruergaard J?rgensen's resignation and leadership changes. Lars Rebien S?rensen joins the board as observer, signaling strategic transition amid market challenges.
Semaglutide vs Tirzepatide in Weight Loss Semaglutide A head-to-head clinical trial shows Tirzepatide significantly outperforms Semaglutide in weight loss and waist reduction among obese non-diabetic adults, with superior efficacy and comparable safety.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a